US equities |
SPCX $166.97 ▲+5.04% NVDA $237.14 ▲+1.36% MU $1,067.29 ▼-0.71% TSLA $375.55 ▲+1.34% MSFT $526.11 ▲+1.66% INTC $117.12 ▼-1.85% SNDK $1,725.12 ▲+0.30% META $742.84 ▲+2.03%
FinancialContent

argenx SE - American Depositary Shares (NQ:ARGX)

906.15 -13.06 (-1.42%)
Delayed Quote Updated: 10:50 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
argenx Highlights 2025 Strategic Priorities
From argenx SE
Via GlobeNewswire
News headline image
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
News headline image
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Looking Into argenx's Recent Short Interest ↗
 
Via Benzinga
News headline image
(ARGX) - Analyzing argenx's Short Interest ↗
 
Via Benzinga
News headline image
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
From argenx SE
Via GlobeNewswire
News headline image
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
News headline image
Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval ↗
Biohaven's BHV-1300 shows >60% IgG reduction in early trials with promising safety data, advancing its MoDE platform and regulatory milestones. 
Via Benzinga
News headline image
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
News headline image
Peering Into argenx's Recent Short Interest ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings For argenx ↗
 
Via Benzinga
News headline image
Peeling Back The Layers: Exploring argenx Through Analyst Insights ↗
 
Via Benzinga
News headline image
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
From argenx SE
Via GlobeNewswire
News headline image
This Bristol-Myers Squibb Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
From Zai Lab Limited
Via Business Wire
News headline image
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
From argenx SE
Via GlobeNewswire
News headline image
This eBay Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
argenx to Participate at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
News headline image
Argenx Q3 Revenue, EPS Beats Excite Bullish Biotech Analysts: 'Most Enviable I&I Pipeline In Entire Industry' ↗
Argenx SE ADR shares jumped after impressive earnings. Analysts raised price targets and noted strong pipeline and global expansion. 
Via Benzinga
News headline image
This Atlassian Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗
 
Via Benzinga
News headline image
This Huntington Ingalls Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
 
Via Benzinga
News headline image
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
News headline image
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
From argenx SE
Via GlobeNewswire
News headline image
argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions
From argenx SE
Via GlobeNewswire
News headline image
Biotech Stocks : Are You A Trader Or A Longer Term Investor? ↗
Biotech bull market is intact as indicated by large cap biopharma and the best performing funds. 
Via Talk Markets
News headline image
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases ↗
Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads. 
Via Investor's Business Daily
News headline image
Snowflake, Hawaiian Electric Industries And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >